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Background. Ivermectin-based mass drug administration has emerged as a promising strategy for the control of scabies and 
impetigo in settings where the diseases are endemic. Current follow-up data are limited to 12 months for the majority of studies. 
Longer-term data are vital to inform the sustainability of interventions.
Methods. We conducted a prevalence survey for scabies and impetigo in 10 villages in Choiseul Province of the Solomon Islands 
36 months after a single round of ivermectin and azithromycin mass drug coadministration. In the primary analysis, we compared 
the prevalence of scabies and impetigo at 36 months to the prevalence at baseline.
Results. At 36 months, the prevalence of scabies was 4.7% (95% confidence interval [CI], 3.6–6.1), which was significantly lower 
than at baseline (18.7%; relative reduction, 74.9%; 95% CI, 61.5%–87.7%; P < .001). The prevalence of impetigo was 9.6% (95% CI, 
8.1%–11.4%), significantly lower than at baseline (24.7%; relative reduction, 61.3%; 95% CI, 38.7%–100%; P < .001). The highest 
prevalence of scabies was among children aged <5 years (12.5%; adjusted odds ratio, 33.2; 95% CI, 6.6–603.2), and the highest prev-
alence of impetigo was among children aged 5–9 years (16.4%; adjusted odds ratio, 8.1; 95% CI, 3.6–21.8).
Conclusions. There was a sustained impact of a single round of ivermectin and azithromycin mass drug coadministration on 
the prevalence of scabies and impetigo 3 years after the intervention. Our data provide further support to adopt this intervention as 
a central component of global scabies control efforts.
Keywords. ivermectin; scabies; impetigo; mass drug administration; neglected tropical diseases.
Scabies, caused by infestation with the mite Sarcoptes scabei var 
hominis, is a significant public health problem in many trop-
ical countries and is particularly common in the Pacific region 
[1–3]. In these settings, the population prevalence of scabies 
can be as high as 20%, with peak prevalence as high as 50% 
among children [2]. Infestation with scabies results in inflam-
mation and itch and is frequently associated with secondary 
bacterial infection (impetigo) caused by Staphylococcus aureus 
and Streptococcus pyogenes (impetigo) [1, 4]. These infections 
can result in more serious complications including septicemia, 
poststreptococcal glomerulonephritis, acute rheumatic fever, 
and rheumatic heart disease [4].
In highly endemic settings, the treatment of individ-
uals and their immediate contacts has no impact on the 
overall community prevalence of scabies due to high rates of 
reinfestation [5, 6]. Because of this, there is increasing interest 
in population-level interventions for the control of scabies. 
Both permethrin- and ivermectin-based mass drug administra-
tions (MDAs) have demonstrated efficacy in single-arm studies 
[7–10]. More recently, ivermectin-based MDA was shown to be 
superior to alternative strategies, including permethrin MDA 
and standard care, in a comparative trial [11]. A  consistent 
finding in these studies is a substantial reduction in impetigo of 
60%–90% following treatment of scabies [7, 11, 12].
There are limited data on the time course with which prev-
alence rebounds following intervention. Most recent published 
data have focused on 12-month outcomes following a single 
round of MDA [11–13]. In an early study that used permethrin-
based MDA, scabies prevalence rebounded within 3 months of 
cessation of the intervention [7], but minimal prevalence re-
bound has been reported at 1 year after ivermectin-based MDA 
[11, 14]. Understanding the longevity of the intervention effect 
is crucial for planning public health measures for scabies, in-
cluding the timing for additional rounds of MDA. Only a single 
study has reported long-term outcomes in the context of mul-
tiple rounds of intervention [14], but there are no data on long-
term outcomes following a single round of MDA.
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In 2015, we conducted a study to assess the prevalence of sca-
bies and impetigo before and after an ivermectin-based MDA 
in a population of more than 25 000 individuals in the Solomon 
Islands. We demonstrated a substantial reduction in the prev-
alence of both scabies and impetigo at 12 months [13, 15]. To 
assess the durability of reductions in prevalence following MDA 
and inform decisions about the optimal interval between rounds 
of MDA, we conducted a follow-up evaluation 36 months after 
the intervention.
METHODS
The methods of the Azithromycin Ivermectin MDA (AIM) study 
have been reported in detail elsewhere [13, 15]. Briefly, AIM 
was a single-arm, before-and-after trial conducted in Choiseul 
Province, 1 of 10 administrative provinces of the Solomon 
Islands. The population was estimated at 26 372 in 2009, with 
the majority of residents on a single large island. The study 
made use of the infrastructure of a planned azithromycin MDA 
conducted for the elimination of trachoma as a public health 
problem [16]. In collaboration with the Ministry of Health and 
Medical Services (MHMS), we integrated an ivermectin-based 
MDA for the control of scabies into this routine activity. At 
baseline (2015), all residents in Choiseul Province were offered 
treatment for both trachoma and scabies. Treatment for tra-
choma consisted of a single dose of oral azithromycin or (when 
azithromycin was contraindicated) a self-administered 6-week 
course of 1% topical tetracycline eye ointment. Treatment for 
scabies consisted of 2 doses of oral ivermectin (200 µg/kg) or 
(when ivermectin was contraindicated, specifically, for preg-
nant or breast-feeding women and children aged <5 years) top-
ical permethrin. Participants who required permethrin were 
given the option to have a trained nurse apply the cream in a 
private room or to apply it themselves at home. The first dose of 
treatment for scabies was administered at the time of treatment 
for trachoma, and the second dose was offered 7 to 14  days 
later. At baseline and at 12 months, 10 villages were randomly 
selected, and all individuals were offered enrollment and exam-
ination for scabies and impetigo. We have previously reported 
both safety outcomes and the 12-month efficacy results with re-
gards to scabies and impetigo [13, 15]. Overall, AIM enrolled 
26 188 participants who, based on the 2009 census, represented 
99.3% of the population. The estimated population coverage of 
the initial dose of treatment for scabies was 98.6%; that of the 
second dose of treatment for scabies was 83.7%.
For the 36-month evaluation, we utilized the same survey 
methodology as at baseline and 12 months. We obtained a com-
plete list of villages in Choiseul Province with estimated popu-
lations from the MHMS. We used simple random selection to 
identify 10 villages with populations of 100–250 residents to 
participate in our 36-month survey. Villages selected in either 
(or both) the baseline and 12-month survey were eligible for 
inclusion in the 36-month survey.
All residents of the selected villages were eligible to partici-
pate in the survey. We obtained written informed consent from 
adults and from the parents/guardians of children. All individ-
uals were examined by a clinician experienced in the diagnosis 
of scabies and impetigo (M. M.). We used the same clinical di-
agnostic methods that were used in the baseline and 12-month 
surveys. Scabies was defined as pruritic inflammatory papules 
with a typical anatomical distribution, such as the webs of the 
fingers, hands, wrists, and ankles, as per Integrated Management 
of Childhood Illness guidelines [17, 18]. Examination excluded 
breasts and genitals, unless requested by participants and 
then only in a separate, private space. Impetigo was defined 
as pustular or ulcerative lesions surrounded by erythema. All 
data were collected directly into the OpenDataKit package on 
Android devices.
Statistical Analyses
For the primary analysis, we compared the prevalence across 
survey villages of scabies and impetigo at 36  months to the 
prevalence at baseline. We calculated the absolute (difference 
between baseline and month 36)  and relative reductions in 
prevalence and their 95% confidence intervals (CIs) based on 
their respective variances [19]. We compared prevalence using 
a χ 2 test and considered P < .05 to be statistically significant.
In further secondary analysis, we fitted a multilevel logistic 
regression model to calculate the odds of scabies and impetigo 
at 1 and 3 years of follow-up compared to baseline after con-
trolling for age and gender. Then, we adjusted for clustering 
by including a random effect for study village. We calculated 
the population-attributable fraction of impetigo due to sca-
bies at baseline, 12 months, and 36 months. We calculated the 
absolute change in prevalence of both scabies and impetigo 
between our 12-month and 36-month surveys. Finally, we 
performed a subgroup analysis on the subset of villages vis-
ited more than once. All analyses were conducted in R version 
3.5.1 [20].
Registration and Ethical Approval
The trial was registered with the Australian and New Zealand 
Trials Registry (ACTRN12615001199505) and approved by the 
Solomon Islands National Research Ethics Committee (15/33) 
and the Royal Children’s Hospital Human Research Ethics 
Committee (35148A). Ethics amendments were granted to un-
dertake the 36-month follow-up survey. As previously reported, 
an independent data safety monitoring committee oversaw the 
original trial intervention.
RESULTS
At the 36-month survey, we examined 1210 individuals across 
the 10 selected villages, which represented 83.3% of the resident 
population of those villages. (At the baseline and 12-month sur-
veys, we had examined 1399 and 1261 individuals, respectively, 
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representing 84.2% and 77.6% of the village populations [13].) 
The demographics of enrolled participants were similar at 
each survey (Table 1). The median age of participants in the 
36-month survey was 12 years (interquartile range, 8–32), and 
546 (45.1%) were male. Four of the selected villages had been 
surveyed at baseline; 2 selected villages had been surveyed at 
the 12-month survey.
Prevalence in Sentinel Villages at Baseline and 36 Months
At the 36-month survey, 57 individuals were diagnosed with 
scabies (4.7%; 95% CI, 3.6–6.1). The prevalence of scabies at 
36  months was significantly lower than at baseline (18.7%), 
with an absolute reduction of 14.0% and relative reduction 
of 74.9% (95% CI, 61.5–87.7%; P <  .001; Table 2). The preva-
lence of scabies varied across the 10 villages from 0.0% to 18.7% 
(Supplementary Table 1).
Children aged <5 years had the highest prevalence of scabies 
at 36 months (12.5%; adjusted odds ratio [AOR], 33.2; 95% CI, 
6.6–603.2; Supplementary Table 1) and the smallest decline in 
prevalence from baseline at both the 12- and 36-month surveys 
(Supplementary Table 2). No cases of crusted scabies were diag-
nosed in the study population at 36 months.
At 36  months, 116 people were diagnosed with impetigo 
(9.6%; 95% CI, 8.1%–11.4%). The prevalence of impetigo was 
significantly lower than at baseline (24.7%), with an absolute 
reduction of 15.2% and relative reduction of 61.3% (95% CI, 
38.7%–100%; P < .001; Table 2). The highest prevalence of impe-
tigo was among children aged 5–9 years (16.4%; AOR, 8.1; 95% 
CI, 3.6–21.8; Supplementary Table 1). Impetigo was diagnosed 
in all 10 study villages, with a range of village-level prevalences 
of 3.7%–17.6% (Supplementary Table 1).
Scabies was significantly associated with impetigo at the 
36-month survey (AOR, 4.7; 95% CI, 2.5–8.5; P  <  .001). 
However, the population-attributable fraction of impetigo due 
to scabies declined across the 3 surveys from 41% at baseline to 
19% and 13% at 12 and 36 months of follow-up, respectively.
Prevalence of Scabies and Impetigo in Sentinel Villages at 12 and 
36 Months
The absolute difference in the prevalence of scabies between the 
12-month and 36-month surveys was +2.4% (95% CI, 0.1–3.9), 
and the absolute difference in the prevalence of impetigo be-
tween the 12-month and 36-month surveys was +3.3% (95% CI, 
0.9–6.4) (Table 2). The absolute changes in prevalence between 
baseline, 12 months, and 36 months were similar across all age 
ranges (Supplementary Table 2).
After adjustment for age and gender, the prevalence of sca-
bies was significantly lower compared to baseline at both the 
12-month (AOR, 0.10; 95% CI, 0.07–0.15) and 36-month 
(AOR, 0.19; 95% CI, 0.14–0.26) surveys. After adjustment for 
age, gender, and presence of scabies, the prevalence of impe-
tigo was significantly lower compared to baseline at both the 
12-month (AOR, 0.31; 95% CI, 0.23–0.41) and the 36-month 
(AOR, 0.39; 95% CI, 0.30–0.50) surveys. Overall, the changes 
in both scabies and impetigo prevalence between 0, 12, and 
36 months were similar between our main survey findings and 
the findings from the subset of villages that were visited more 
than once (Supplementary Table 3).
Table 1. Demographic Characteristics of Participants in Each Survey
Characteristic Baseline Survey 12-Month Survey 36-Month Survey
Gender, n (%) Female 711 (50.8) 691 (54.8) 664 (54.9)
Male 688 (49.2) 570 (45.2) 546 (45.1)
Age, mean (standard deviation), y 21.6 (18.6) 22.2 (18.6) 20.3 (18.5)
Age group, n (%), y <5 231 (16.5) 155 (12.3) 160 (13.2)
5–9 250 (17.9) 229 (18.2) 269 (22.2)
10–14 225 (16.1) 209 (16.6) 277 (22.9)
15–24 175 (12.5) 227 (18.0) 121 (10)
25–34 177 (12.7) 130 (10.3) 118 (9.8)
≥35 341 (24.4) 311 (24.7) 265 (21.9)
Table 2. Prevalence of Scabies and Impetigo at Baseline, 12, and 36 Months
Prevalence at  
Baseline
(95% CI)
n/N
Prevalence at  
12 Months
(95% CI)
n/N
Prevalence at  
36 Months
(95% CI)
n/N
Absolute  
Reduction in 
Prevalence at 12 
Monthsa
(95% CI)
Relative 
Reduction in 
Prevalence at 12 
Monthsa
(95% CI)
Absolute 
Reduction in 
Prevalence at 36 
Monthsa
(95% CI)
Relative 
Reduction in 
Prevalence at 36 
Monthsa
(95% CI)
Absolute Change 
in Prevalence 
Between 12 and 
36 Months
(95% CI)
Scabies 18.7% (16.6 to 20.8) 
(261/1399)
2.3% (1.6 to 3.3) 
(29/1261)
4.7% (3.6 to 6.1) 
(57/1210)
16.6%  
(14.5 to 18.8)
89%  
(77.5 to 100)
14.0%  
(11.5 to 16.4)
74.9%  
(61.5 to 87.7)
+2.4%  
(+0.1 to + 3.9)
Impetigo 24.8% (22.6 to 27.2) 
(347/1399)
6.4% (5.2 to 8.0) 
(81/1261)
9.6% (8.1 to 11.4) 
(116/1210)
18.7%  
(16.2 to 21.3)
75%  
(65.2 to 85.7)
15.2%  
(9.6 to 24.8)
61.3%  
(38.7 to 100)
+3.2%  
(+0.9 to +6.4)
Abbreviation: CI, confidence interval.
aCompared to baseline prevalence.
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DISCUSSION
In this study, we demonstrate the sustained impact of a single 
round of ivermectin-based MDA on the prevalence of scabies 
and impetigo for 3 years after intervention. The relative reduc-
tion in scabies and impetigo remained >70% and >60%, respec-
tively, at 3 years compared to baseline, representing an ongoing 
substantial public health benefit from MDA. While scabies and 
impetigo both increased between month 12 and month 36, the 
point estimates and CIs are consistent with relatively small in-
creases over the 2-year period. Our data suggest that while fur-
ther intervention may be required to sustain these gains, MDA 
for scabies may not need to be delivered annually to confer a 
significant reduction in morbidity.
While the province-level prevalence of scabies remained low, 
there was considerable heterogeneity in prevalence; in 1 sam-
pled village at 36  months, the prevalence had returned to its 
baseline level. In this village, the prevalence of impetigo re-
mained lower than at baseline and was also lower than that 
found in several other villages at 36 months. We did not iden-
tify any cases of crusted scabies or other possible explanations 
for the relatively rapid recrudescence in scabies prevalence in 
this village. District-level prevalence estimates may mask focal 
disease “hot spots” after MDA. Because we only surveyed 10 
villages at the 36-month visit, we cannot exclude the possi-
bility that scabies may have also returned to baseline levels (or 
greater) in other villages in Choiseul Province. Conversely, ap-
parent hot spots may simply represent stochastic noise arising 
from sampling. If mechanisms for identifying and confirming 
such hot spots could be validated, mop-up targeted MDA might 
become a viable strategy to use in these communities, rather 
than deploying further rounds of district-level intervention.
The prevalence of impetigo was substantially lower at 
36 months than at baseline [13]. Our data confirm that in this 
setting, scabies is the major driver for impetigo and that treat-
ment of scabies results in marked declines in impetigo preva-
lence. At 3  years, the population-attributable fraction burden 
of impetigo had declined markedly, suggesting that additional 
interventions beyond ivermectin-based MDA may be necessary 
to further reduce impetigo prevalence. We previously demon-
strated that the addition of single-dose azithromycin adminis-
tered at the same time as ivermectin as part of MDA does not 
appear to drive greater reductions in impetigo [12]. It is plau-
sible that the remaining impetigo burden is a result of multiple 
distinct risk factors and mechanisms, such as skin breaches 
from localized trauma, insect bites, and fungal and other skin 
conditions. With a sufficiently low prevalence of impetigo, as 
achieved following ivermectin-based MDA, a case-management 
strategy could potentially be used to control residual disease.
At both the 12- and 36-month follow-up visits, the smallest 
relative reductions in scabies and impetigo prevalence were 
among children aged 0–4 years, the group who received treat-
ment with permethrin rather than ivermectin. The reductions 
seen in this age group were similar to those seen in the per-
methrin MDA arm of the Skin Health Intervention Fiji Trial 
in Fiji [11]. On an individual level, some data suggest that per-
methrin is equivalent, if not superior, to ivermectin for the 
treatment of scabies [21–23]. However, in an MDA context, 
reduced adherence or inadequate application of permethrin 
compared to directly observed therapy with ivermectin might 
attenuate its efficacy. Collectively, these data highlight the need 
for additional strategies to target scabies in this high-risk age 
group. One option may be to lower the minimum age and/or 
weight limit for ivermectin administration.
With the World Health Organization having designated sca-
bies as a neglected tropical disease, there is a pressing need for 
evidence to inform guidelines for control interventions. In our 
study, reported coverage was very high, above 95% for the first 
dose and above 80% for the second dose of treatment. The re-
sults suggest that this coverage with 2-dose ivermectin-based 
MDA may have a large and sustained impact on the preva-
lence of both scabies and impetigo at 3  years. Our study was 
nonrandomized and performed in a relatively isolated island 
population. Despite these limitations, it represents a significant 
contribution to the emerging data on the use of ivermectin-
based MDA for the control of scabies, providing further sup-
port for adoption of this intervention as the central component 
of global scabies control efforts.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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